The RE-DUAL PCI trial investigated patients with atrial fibrillation post-percutaneous coronary intervention. Dabigatran dual therapy (DDT) reduced bleeding risk vs warfarin triple therapy (WTT)

This subanalysis investigated patients categorized according to proton pump inhibitor use at baseline

Clinical efficacy endpoints were similar in DDT and WTT groups regardless of proton pump inhibitor use. DDT reduced bleeding risk vs WTT regardless of proton pump inhibitor use